Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 2015—Horizon Discovery Group has signed a supply and commercialization agreement with Thermo Fisher Scientific. Under the terms of the agreement, Thermo Fisher will market and distribute Horizon’s X-MAN human haploid and diploid isogenic cell line collection and will further offer the X-MAN haploid cell line generation service to its worldwide customer base.
June 2015—Agena Bioscience released the LungFusion Panel for rapid and sensitive identification of oncogenic ALK, RET, and ROS1 gene fusions in non-small cell lung cancer tumors. Using as little as 10 ng of complementary DNA template, the research-use-only, single-well panel identifies expressed translocations of known clinical relevance in formalin-fixed, paraffin-embedded and fresh frozen tissue samples.
June 2015—Bio-Rad is extending its agreement with Beckman Coulter and has named the company exclusive global distributor of Bio-Rad’s Access HIV combo assay and the Access hepatitis C virus assay in select geographies (the products are not available in the U.S. or Vietnam).
June 2015—Ventana Medical Systems has entered into a master collaboration agreement with Astellas Pharma, a research-and-development–driven pharmaceutical company headquartered in Japan, to develop novel automated tissue diagnostics in support of therapeutic compounds in development.
June 2015—Qiagen has expanded its relationship with BGI to provide Qiagen’s Ingenuity Variant Analysis in integrated bioinformatics for all customers of BGI’s sequencing services.
June 2015—Siemens Healthcare Diagnostics has launched pediatric thyroid reference intervals for its Advia Centaur systems, Dimension Vista systems, and Dimension EXL systems to enhance the interpretation of thyroid assay testing in children and to optimize patient care.
June 2015—LeukoVantage, an evidence-based genomic test service that aids in the diagnosis, prognosis, monitoring, and selection of treatment for myeloid neoplasms is now available from Quest Diagnostics. The lab-developed test uses next-generation sequencing, polymerase chain reaction, and other techniques to interrogate DNA from leukocytes in blood or bone marrow specimens for the presence of mutations in 30 genes most frequently associated with myeloid neoplasms.
June 2015—Streck has introduced CD-Chex TdT Plus, a flow cytometry control assayed for TdT, CD1a, CD34, and cCD3. CD-Chex TdT Plus can be used as quality control material for evaluating intracellular and surface antigens including CD1a, CD2, CD4, CD5, CD7, CD8, CD34, cytoplasmic CD3, and nuclear TdT (terminal deoxynucleotidyl transferase).
June 2015—Beckman Coulter’s automated Aquios CL Flow Cytometer has received FDA clearance for use in the clinical laboratory. With its small footprint and high precision, the “load and go” instrument has been designed for the Lean laboratory. With integrated automated sample preparation, Aquios CL Flow Cytometer delivers first results within 20 minutes for routine applications such as immunophenotyping.
June 2015—Danaher Corp. will separate into two independent, publicly traded companies. The transaction will create a science and technology growth company that will retain the Danaher name. Collectively, its businesses generated approximately $16.5 billion in revenues (including Pall Corp., which Danaher has signed an agreement to acquire) in their most recently completed fiscal years.
